MedTrace Logo

Efficacy and Safety of PRJ212 to Improve the Memory of Patients With Mild Severity Alzheimer's Disease

NCT02991235 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-01-19

No results posted yet for this study

Summary

A 6-month randomized, double-blind and placebo-controlled, followed by a 6-month open label extension study.

Conditions

  • Alzheimer Disease

Interventions

DIETARY_SUPPLEMENT

PRJ212

6 capsules of study product will be taken daily and orally.

DIETARY_SUPPLEMENT

Placebo

6 capsules of study product will be taken daily and orally.

Sponsors & Collaborators

  • Bioiberica

    lead INDUSTRY

Principal Investigators

  • Martinez · Bioiberica, S.A.

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2018-07-31
Completion
2018-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02991235 on ClinicalTrials.gov